Supplementary Data for: Highly selective, allosteric inhibition of TYK2 with oral ESK 001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

This dataset contains supplementary data for the following publication: Highly selective, allosteric inhibition of TYK2 with oral ESK 001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study published in the Journal of the American Academy of Dermatology. Supplementary material includes patient eligibility criteria, list of investigators, and 7 supplementary figures.